Sunitinib-induced reversible posterior leukoencephalopathy syndrome after rifampin discontinuation.
- Author:
Mi Jung KIM
1
;
Hee Jun KIM
;
Hyun Mi BAE
;
Sung Hoon SIM
;
Jeong Ok LEE
;
Yongjun CHA
;
Se Hoon LEE
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. shlee119@snu.ac.kr
- Publication Type:Case Report
- Keywords:
Sunitinib;
Posterior leukoencephalopathy syndrome;
Carcinoma;
Renal cell
- MeSH:
Aged;
Benzamides;
Carcinoma, Renal Cell;
Diarrhea;
Fatigue;
Female;
Gastrointestinal Stromal Tumors;
Hand-Foot Syndrome;
Humans;
Hypertension;
Indoles;
Nausea;
Piperazines;
Posterior Leukoencephalopathy Syndrome;
Protein-Tyrosine Kinases;
Pyrimidines;
Pyrroles;
Rifampin;
Stomatitis;
Imatinib Mesylate
- From:Korean Journal of Medicine
2009;77(Suppl 1):S188-S191
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Sunitinib is an oral tyrosine kinase inhibitor with anti-angiogenic activity that is used for the treatment of advanced renal cell carcinoma and advanced gastrointestinal stromal tumors after failure on imatinib. The most common adverse effects of sunitinib are fatigue, diarrhea, nausea, stomatitis, hypertension, hand-foot syndrome, and cytopenia. Sunitinib was recently reported to be associatedwith reversible posterior leukoencephalopathy syndrome (RPLS). Here, we report the case of a 76-year-old woman with sunitinib- induced RPLS that developed after rifampin discontinuation.
